Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Commodore Capital

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 22
Average round size
info
The average size of a deal this fund participated in
$109M
Portfolio companies 18
Rounds per year 4.40
Lead investments 1
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.09
Exits 14
Key employees Soon
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Therapeutics
  • Health Care
  • Pharmaceutical
  • Medical

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Commodore Capital:
Typical Co-investors
Commodore Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Commodore Capital:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
1818 Venture Capital Guernsey, Guernsey, NA - Guernsey
Acorn Bioventures New York, New York, United States
Acuity Brands Atlanta, Georgia, United States
Bincot -
Cheval Holdings -
Concord Partners Massachusetts, United States, Wellesley
GeneScience Pharmaceuticals -
Hacking Health Accelerator Canada, Montréal, Quebec
Hermann Companies Arkansas, Paragould, United States
Kissei Pharmaceutical Japan, Matsumoto, Nagano Prefecture
MEST Express accelerator Accra, Ghana, Greater Accra
Old Ironsides Energy Boston, Massachusetts, United States
Ontario Pension Board Canada, Ontario, Toronto
Orgain California, Irvine, United States
Technologies SAS -
Tokyo Commodity Exchange -
Trends Media -
Yiguo Group Changning, China, Shanghai

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Third Harmonic Bio

Biotechnology
Life Science
$105M16 Jan 2022 Cambridge, Massachusetts, United States

Shoreline Biosciences

Biotechnology
Life Science
Medical
$43M07 Feb 2021 San Diego, California, United States
News
Nimbus Therapeutics Announces $105 Million Private Financing to Advance Pipeline Including Multiple Clinical Programs

– Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, announced the closing of a $105 million private financing round.
– The round was led by BVF Partners L.P., with participation from existing investors including RA Capital Management and Atlas Venture.
Access Biotechnology, Commodore Capital, Logos Capital, Surveyor Capital (a Citadel company), and a large alternative asset manager joined as new investors in this financing.
– In addition to the Phase 2 studies of Nimbus’ allosteric TYK2 inhibitor, the financing will support a first-in-human study of the company’s HPK1 inhibitor candidate in cancer patients with solid tumors, which will begin later this year, and will accelerate preclinical programs against multiple targets in oncology and immunology.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Commodore Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 22
Average round size 109M
Rounds per year 4.40
Peak activity year 2023
Lead investments 1
Follow on index 0.09
Exits 14
Group Appearance index 1.00

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Third Harmonic Bio

Biotechnology
Life Science
$105M16 Jan 2022 Cambridge, Massachusetts, United States

Shoreline Biosciences

Biotechnology
Life Science
Medical
$43M07 Feb 2021 San Diego, California, United States
Crunchbase icon

Content report

The following text will be sent to our editors: